期刊文献+

血浆置换术救治急危重血栓性血小板减少性紫癜 被引量:5

Plasma exchange as rescue therapy in critically ill patients with thrombotic thrombocytopenic purpura
下载PDF
导出
摘要 目的:提高血浆置换术治疗血栓性血小板减少性紫癜(TTP)的认识及急危重患者抢救成功率。方法:报道2例急危重血栓性血小板减少性紫癜患者主要的临床特征和实验室异常,以血浆置换术为主要措施的救治过程,并进行文献复习。结果:昏迷多日的2例急危重患者通过血浆置换术等主要治疗措施均获成功救治。结论:血栓性血小板减少性紫癜诊断可以通过精神症状、发热和贫血等临床特征及微血管病性溶血、血小板减少等实验室特点早期得到诊断,血浆置换术仍是最有效的主要治疗措施,即使对急危重患者昏迷多日也仍然有效。 Objective: To improve the knowledge on the significance of plasma exchange as rescue therapy in critically ill patients with thrombotic thrombocytopenic purpura( TTP) for improving the survival of such patients.Methods: Case report was performed in two critically ill patients with TTP concerning clinical pictures,laboratory findings and procedures in life-saving,and related literatures were reviewed.Results: Two patients being coma for several days were successfully treated through plasma exchange.Conclusion: Clinical diagnosis of TTP can rely on psychiatric symptoms,fever and anemia as well laboratory findings including microvascular haemolysis and thrombocytopenia.Plasma exchange serves as important and effective therapeutic strategy for critically ill patients with TTP,even if patient are suffering from coma for several days.
作者 苏贵平 韦中玲 刘善浩 SU Guiping WEI Zhongling LIU Shanhao(Department of Hematology,The First Affiliated Hospital of Wannan Medical College,Wuhu 241001,China)
出处 《皖南医学院学报》 CAS 2016年第4期343-346,共4页 Journal of Wannan Medical College
关键词 血小板减少 紫癜 血栓性 血浆置换 危重 thrombocytopenia purpura thrombosis plasma exchange critically ill
  • 相关文献

参考文献2

二级参考文献43

  • 1Scully M, McDonald V, Cavenagh J, et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura[J]. Blood, 2011, 118(7):1746-1753.
  • 2Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura[J]. Blood, 2008, 112(1):11-18.
  • 3Shumak KH, Rock GA, Nair RC. Late relapses in patients successfully treated for thrombotic thrombocytopenic purpura. Canadian Apheresis Group[J]. Ann Intern Med, 1995, 122(8): 569-572.
  • 4Scully M, Yarranton H, Liesner R, et al. Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features[J]. Br J Haematol, 2008, 142(5):819-826.
  • 5Peyvandi F, Lavoretano S, Palla R, et al. ADAMTS13 andmanti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission[J]. Haematologica, 2008, 93(2): 232-239.
  • 6Kremer Hovinga JA, L?mmle B. Role of ADAMTS13 in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura[J]. Hematology Am Soc Hematol Educ Program, 2012, 2012:610-616.
  • 7Ferrari S, Mudde GC, Rieger M, et al. IgG subclass distribution of anti-ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura[J]. J Thromb Haemost, 2009, 7(10): 1703-1710.
  • 8Allford SL, Hunt BJ, Rose P, et al. Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias[J]. Br J Haematol, 2003, 120(4):556-573.
  • 9Blombery P, Scully M. Management of thrombotic thrombocytopenic purpura: current perspectives[J]. J Blood Med, 2014, 5:15-23.
  • 10Crawley JT, Scully MA. Thrombotic thrombocytopenic purpura: basic pathophysiology and therapeutic strategies[J]. Hematology Am Soc Hematol Educ Program, 2013, 2013:292-299.

共引文献25

同被引文献46

引证文献5

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部